Plus   Neg

Haemonetics Not Issuing FY21 Outlook At This Time Amid COVID-19 - Quick Facts

While reporting financial results for the fourth quarter on Tuesday, healthcare company Haemonetics Corp. (HAE) said it is not issuing guidance for the full-year 2020 at this time, due to the uncertainty around the full impact and duration of the COVID-19 pandemic, and the nature and timing of the associated economic recovery.

Due to the timing of the COVID-19 pandemic and its progression during the fourth quarter, Haemonetics said it experienced limited impact on its fiscal 2020 financial results.

While the duration and additional implications of the pandemic remain uncertain, the company believes it will see higher impacts from the COVID-19 pandemic on its fiscal 2021 results.

This will be driven by the continued effects of social distancing guidelines and stay at home orders, declines of elective surgeries, restricted vendor access at customer sites, reallocation of hospital resources to critical ICU needs and other changes that may still arise as a result of COVID-19.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Guitar Center Inc., a retailer of musical instruments, lessons, repairs and rentals, has filed for Chapter 11 bankruptcy reorganization, aiming to significantly reduce its debt and continue its business amid ongoing struggles following the coronavirus pandemic. The company, which operates nearly 300 stores across the U.S., expects to complete the process before the end of this year. Amazon is offering new "Spoiler Free" ways to keep gifts a surprise, as well as to track, receive and pick up orders this holiday season. According to the company, the new features would help customers to face the challenge of keeping those special gifts under wraps as many families are opting to stay home amid the coronavirus pandemic. AstraZeneca Plc and Oxford University's coronavirus vaccine candidate AZD1222 is found to be 70 percent effective on average against Covid-19, according to the British pharmaceutical giant. AstraZeneca plans to immediately prepare regulatory submission of the data to worldwide authorities for conditional or early approval. The company will also ask for an Emergency Use Listing from the WHO.
Follow RTT